Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The award is given to CFOs for outstanding performance as corporate stewards.
Since joining Evolus in 2022, Mrs. Beaver has played a critical role in positioning the company for continued growth and success. In 2023, she supported and led the financial execution of milestones including the company’s licensing agreements which expanded its product portfolio with the addition of late-stage dermal fillers in the U.S. and European markets while broadening the estimated total addressable market by 78% to approximately $6 billion. She also played a significant role in supporting the geographic expansion of the company’s commercial footprint to Austria, Germany, and Italy. Sandra continues to lead the organization to financial success, guiding critical processes to drive smart strategic decisions and broadening the company’s portfolio while maintaining operating expense discipline.
"On behalf of the entire Evolus team, we congratulate Sandra on receiving this well-deserved recognition. In her role as CFO, Sandra’s strong strategic leadership and vision has been instrumental in the success of our Company. Her key insights, exceptional performance and many contributions to our company have guided us through complex business scenarios with seamless precision. Sandra has played a pivotal role in continuing the fast-paced growth of our business, as well as laid the financial pathway to secure a licensing agreement to expand our product portfolio of aesthetic consumer brands,” said David Moatazedi, President and Chief Executive Officer of Evolus.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510629398/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: [email protected]
Media:
Email: [email protected]
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.